Vimarsana
Biggest News Aggregation in the World

Page 2 - Clinical Program Leader News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Program Leader. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program Leader Today - Breaking & Trending Today

ViroCell, the UK's first clinical trial focused viral vector manufacturer, announces its official launch - Vimarsana News

ViroCell, the UK's first clinical trial focused viral vector manufacturer, announces its official launch

ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces its official launch. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy ...

FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma - Vimarsana News

FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma

Share this article Share this article WALTHAM, Mass., March 1, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO),  a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is...